KR102316842B1 - 인간화 분화 클러스터 274 유전자를 갖는 비인간 동물 - Google Patents

인간화 분화 클러스터 274 유전자를 갖는 비인간 동물 Download PDF

Info

Publication number
KR102316842B1
KR102316842B1 KR1020177016266A KR20177016266A KR102316842B1 KR 102316842 B1 KR102316842 B1 KR 102316842B1 KR 1020177016266 A KR1020177016266 A KR 1020177016266A KR 20177016266 A KR20177016266 A KR 20177016266A KR 102316842 B1 KR102316842 B1 KR 102316842B1
Authority
KR
South Korea
Prior art keywords
human
gene
exon
rodent
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177016266A
Other languages
English (en)
Korean (ko)
Other versions
KR20170101910A (ko
Inventor
엘레나 부로바
야준 탕
카-만 비너스 라이
앤드류 제이. 머피
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020217033684A priority Critical patent/KR102457921B1/ko
Publication of KR20170101910A publication Critical patent/KR20170101910A/ko
Application granted granted Critical
Publication of KR102316842B1 publication Critical patent/KR102316842B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177016266A 2014-12-09 2015-12-09 인간화 분화 클러스터 274 유전자를 갖는 비인간 동물 Active KR102316842B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217033684A KR102457921B1 (ko) 2014-12-09 2015-12-09 인간화 분화 클러스터 274 유전자를 갖는 비인간 동물

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462089549P 2014-12-09 2014-12-09
US62/089,549 2014-12-09
US201562106525P 2015-01-22 2015-01-22
US62/106,525 2015-01-22
PCT/US2015/064626 WO2016094481A1 (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217033684A Division KR102457921B1 (ko) 2014-12-09 2015-12-09 인간화 분화 클러스터 274 유전자를 갖는 비인간 동물

Publications (2)

Publication Number Publication Date
KR20170101910A KR20170101910A (ko) 2017-09-06
KR102316842B1 true KR102316842B1 (ko) 2021-10-25

Family

ID=55024286

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177016266A Active KR102316842B1 (ko) 2014-12-09 2015-12-09 인간화 분화 클러스터 274 유전자를 갖는 비인간 동물
KR1020217033684A Active KR102457921B1 (ko) 2014-12-09 2015-12-09 인간화 분화 클러스터 274 유전자를 갖는 비인간 동물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217033684A Active KR102457921B1 (ko) 2014-12-09 2015-12-09 인간화 분화 클러스터 274 유전자를 갖는 비인간 동물

Country Status (27)

Country Link
US (4) US9913461B2 (https=)
EP (3) EP4399969A3 (https=)
JP (3) JP2018500896A (https=)
KR (2) KR102316842B1 (https=)
CN (2) CN113412818B (https=)
AU (3) AU2015360667B2 (https=)
BR (1) BR112017011982A2 (https=)
CA (1) CA2968675C (https=)
CY (1) CY1123723T1 (https=)
DK (2) DK3808775T3 (https=)
ES (2) ES2982515T3 (https=)
FI (1) FI3808775T3 (https=)
HR (2) HRP20202034T1 (https=)
HU (2) HUE067123T2 (https=)
IL (3) IL282649B (https=)
LT (2) LT3808775T (https=)
MX (1) MX2017007636A (https=)
NZ (2) NZ731954A (https=)
PL (1) PL3808775T3 (https=)
PT (2) PT3808775T (https=)
RS (2) RS61218B1 (https=)
RU (1) RU2711729C2 (https=)
SG (2) SG11201703931QA (https=)
SI (2) SI3808775T1 (https=)
SM (2) SMT202400313T1 (https=)
WO (1) WO2016094481A1 (https=)
ZA (1) ZA201703263B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113412818B (zh) 2014-12-09 2022-11-04 瑞泽恩制药公司 具有人源化分化簇274基因的非人动物
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
SG11201806176PA (en) 2016-02-04 2018-08-30 Regeneron Pharma Non-human animals having an engineered angptl8 gene
DK3422845T3 (da) 2016-02-29 2021-08-30 Regeneron Pharma Gnavere med et humaniseret tmprss-gen
WO2018001241A1 (zh) * 2016-06-28 2018-01-04 北京百奥赛图基因生物技术有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041120A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
WO2019072241A1 (en) * 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
WO2019114768A1 (en) 2017-12-12 2019-06-20 Biocytogen Jiangsu Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
CN110846321B (zh) * 2018-08-21 2021-11-19 中国科学院动物研究所 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途
US20210380978A1 (en) * 2018-10-15 2021-12-09 The Brigham And Women`S Hospital, Inc. The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
CN109452229B (zh) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 狗源化pd-1基因改造动物模型的制备方法及应用
CN109979539B (zh) * 2019-04-10 2020-10-02 电子科技大学 基因序列优化方法、装置及数据处理终端
WO2022174823A1 (en) * 2021-02-19 2022-08-25 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd3 genes
CN112999368A (zh) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 人源化模型进行药效评价方法的建立

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
JP2012050451A (ja) 2003-12-24 2012-03-15 G2 Inflammation Pty Ltd ヒトまたはヒト化Ｃ５ａＲをコードするポリヌクレオチドを含むトランスジェニック非ヒト哺乳動物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6485964B1 (en) * 1995-03-20 2002-11-26 Arris Pharmaceutical Corporation Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
EP1320599A2 (en) 2000-06-28 2003-06-25 Genetics Institute, LLC Pd-l2 molecules: pd-1 ligands and uses therefor
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2507882A1 (en) * 2002-12-16 2004-07-22 Genentech, Inc. Transgenic mice expressing human cd20
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
DK1810026T3 (en) 2004-10-06 2018-07-16 Mayo Found Medical Education & Res B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
PT1907424E (pt) * 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
RU2573912C2 (ru) 2008-10-08 2016-01-27 Интрексон Корпорейшн Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
EP2470671B1 (en) * 2009-08-28 2014-12-24 Regeneron Pharmaceuticals, Inc. Antikine antibodies that bind to multiple cc chemokines
EP4502152A3 (en) 2009-10-06 2025-04-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
WO2011060357A2 (en) 2009-11-16 2011-05-19 The Ohio State University Engineered xenogeneic cells for repair of biological tissue
PL2504364T3 (pl) * 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
CA2784953C (en) * 2009-12-21 2018-05-22 Regeneron Pharmaceuticals, Inc. Humanized fc.gamma.r mice
EP2555778A4 (en) * 2010-04-06 2014-05-21 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
SG10202008003VA (en) 2011-02-15 2020-10-29 Regeneron Pharma Humanized m-csf mice
CN108866101A (zh) 2011-10-28 2018-11-23 瑞泽恩制药公司 人源化il-6和il-6受体
SMT201900478T1 (it) 2011-10-28 2019-09-09 Regeneron Pharma Topi con complesso maggiore di istocompatibilita' geneticamente modificati
SMT202200205T1 (it) 2011-10-28 2022-07-21 Regeneron Pharma Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii
EP3696262A1 (en) 2011-11-23 2020-08-19 The Trustees Of The University Of Pennsylvania Use of pdl1 expressing cells to convert t cells into regulatory t cells
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
US9574004B2 (en) * 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
FI2892330T3 (fi) 2012-09-07 2023-03-25 Univ Yale Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi
MX377561B (es) 2012-11-05 2025-03-10 Regeneron Pharma Animales no humanos genéticamente modificados y métodos de uso de los mismos.
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
MX384291B (es) 2013-02-20 2025-03-14 Regeneron Pharma Modificación genética de ratas.
CN111484999B (zh) * 2013-02-20 2024-10-25 瑞泽恩制药公司 人源化的t细胞共受体的小鼠
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
EP3699190B9 (en) 2013-02-22 2023-10-04 Regeneron Pharmaceuticals, Inc. Murine cell expressing humanized major histocompatibility complex
DK3456831T3 (da) * 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
EP3293275B1 (en) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
TR201901782T4 (tr) 2013-09-23 2019-03-21 Regeneron Pharma İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
CA2929846C (en) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CN111690052B (zh) 2014-04-08 2024-06-04 瑞泽恩制药公司 具有人源化FC-γ受体的非人动物
NO2785538T3 (https=) 2014-05-07 2018-08-04
MX2016014995A (es) 2014-05-19 2017-03-31 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
IL287519B2 (en) * 2014-06-19 2024-01-01 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
RU2726446C2 (ru) 2014-11-24 2020-07-14 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
HUE064960T2 (hu) 2014-12-05 2024-04-28 Regeneron Pharma Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok
CN113412818B (zh) 2014-12-09 2022-11-04 瑞泽恩制药公司 具有人源化分化簇274基因的非人动物
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
JP2012050451A (ja) 2003-12-24 2012-03-15 G2 Inflammation Pty Ltd ヒトまたはヒト化Ｃ５ａＲをコードするポリヌクレオチドを含むトランスジェニック非ヒト哺乳動物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nat Rev Genet. vol.13 no.1 pp.14-20(2011)

Also Published As

Publication number Publication date
KR20170101910A (ko) 2017-09-06
CN107257624A (zh) 2017-10-17
JP2022184973A (ja) 2022-12-13
JP7488861B2 (ja) 2024-05-22
NZ770783A (en) 2024-11-29
AU2015360667A1 (en) 2017-06-08
AU2021286369B2 (en) 2025-03-27
JP2018500896A (ja) 2018-01-18
IL282649B (en) 2022-07-01
AU2021286369A1 (en) 2022-01-20
NZ731954A (en) 2024-11-29
US10881086B2 (en) 2021-01-05
JP2021003130A (ja) 2021-01-14
JP7145920B2 (ja) 2022-10-03
HUE067123T2 (hu) 2024-10-28
ES2982515T3 (es) 2024-10-16
IL252695A0 (en) 2017-08-31
AU2015360667B2 (en) 2021-09-23
RS61218B1 (sr) 2021-01-29
RU2017123754A3 (https=) 2019-06-24
CN113412818B (zh) 2022-11-04
RU2017123754A (ru) 2019-01-10
SG11201703931QA (en) 2017-06-29
SMT202100148T1 (it) 2021-05-07
HRP20240855T1 (hr) 2024-10-11
EP3230320B1 (en) 2020-10-07
SI3230320T1 (sl) 2021-02-26
IL275864A (en) 2020-08-31
MX2017007636A (es) 2018-03-28
ES2841353T3 (es) 2021-07-08
IL275864B (en) 2021-05-31
WO2016094481A1 (en) 2016-06-16
RU2711729C2 (ru) 2020-01-21
LT3230320T (lt) 2021-01-11
US20240389563A1 (en) 2024-11-28
EP3808775B1 (en) 2024-04-17
US12089575B2 (en) 2024-09-17
DK3230320T3 (da) 2021-01-11
RS65664B1 (sr) 2024-07-31
AU2025204751A1 (en) 2025-07-17
ZA201703263B (en) 2023-02-22
PT3808775T (pt) 2024-07-09
BR112017011982A2 (pt) 2018-01-16
EP4399969A3 (en) 2024-10-30
SG10202100792XA (en) 2021-03-30
SMT202400313T1 (it) 2024-09-16
CN113412818A (zh) 2021-09-21
EP3808775A1 (en) 2021-04-21
CA2968675A1 (en) 2016-06-16
CN107257624B (zh) 2021-07-13
LT3808775T (lt) 2024-07-10
US20160157469A1 (en) 2016-06-09
US20210105983A1 (en) 2021-04-15
PL3808775T3 (pl) 2024-08-19
KR102457921B1 (ko) 2022-10-25
KR20210130251A (ko) 2021-10-29
EP3230320A1 (en) 2017-10-18
SI3808775T1 (sl) 2024-08-30
DK3808775T3 (da) 2024-07-01
PT3230320T (pt) 2021-01-08
CY1123723T1 (el) 2022-03-24
IL252695B (en) 2020-07-30
IL282649A (en) 2021-06-30
US20180160663A1 (en) 2018-06-14
HUE052606T2 (hu) 2021-05-28
US9913461B2 (en) 2018-03-13
EP4399969A2 (en) 2024-07-17
CA2968675C (en) 2023-10-17
HRP20202034T1 (hr) 2021-02-19
FI3808775T3 (fi) 2024-07-02

Similar Documents

Publication Publication Date Title
AU2021286369B2 (en) Non-human animals having a humanized cluster of differentiation 274 gene
JP7720349B2 (ja) ヒト化プログラム細胞死１遺伝子を持つ非ヒト動物
KR20160085798A (ko) 인간화된 증식-유도 리간드 유전자를 가지고 있는 비-인간 동물
HK40108429A (en) Non-human animals having a humanized cluster of differentiation 274 gene
HK40040582A (en) Non-human animals having a humanized cluster of differentiation 274 gene
HK40040582B (en) Non-human animals having a humanized cluster of differentiation 274 gene
HK40023109A (en) Non-human animals having a humanized programmed cell death 1 gene
HK1238254B (en) Non-human animals having a humanized cluster of differentiation 274 gene
HK1238254A1 (en) Non-human animals having a humanized cluster of differentiation 274 gene
HK1231084A1 (en) Non-human animals having a humanized programmed cell death 1 gene
HK1231084B (en) Non-human animals having a humanized programmed cell death 1 gene

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170614

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191125

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20201216

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210311

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210720

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211019

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211019

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211020

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee